Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published December 4, 2012 | Supplemental Material + Published
Journal Article Open

Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor

Abstract

The glucagon-like peptide 1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) involved in insulin synthesis and regulation; therefore, it is an important drug target for treatment of diabetes. However, GLP1R is a member of the class B1 family of GPCRs for which there are no experimental structures. To provide a structural basis for drug design and to probe class B GPCR activation, we predicted the transmembrane (TM) bundle structure of GLP1R bound to the peptide Exendin-4 (Exe4; a GLP1R agonist on the market for treating diabetes) using the MembStruk method for scanning TM bundle conformations. We used protein–protein docking methods to combine the TM bundle with the X-ray crystal structure of the 143-aa N terminus coupled to the Exe4 peptide. This complex was subjected to 28 ns of full-solvent, full-lipid molecular dynamics. We find 14 strong polar interactions of Exe4 with GLP1R, of which 8 interactions are in the TM bundle (2 interactions confirmed by mutation studies) and 6 interactions involve the N terminus (3 interactions found in the crystal structure). We also find 10 important hydrophobic interactions, of which 4 interactions are in the TM bundle (2 interactions confirmed by mutation studies) and 6 interactions are in the N terminus (6 interactions present in the crystal structure). Thus, our predicted structure agrees with available mutagenesis studies. We suggest a number of mutation experiments to further validate our predicted structure. The structure should be useful for guiding drug design and can provide a structural basis for understanding ligand binding and receptor activation of GLP1R and other class B1 GPCRs.

Additional Information

© 2012 National Academy of Sciences. Contributed by William A. Goddard III, October 18, 2012 (sent for review July 9, 2012). Published online before print November 19, 2012. The MembStruk studies by J.H. were funded by Allozyne (Ken Grabstein). The final optimization of the structure and analysis (A.K.) was funded by Sanofi-Aventis (Ken Wertman). Author contributions: A.K., J.H., R.A., and W.A.G. designed research; A.K. and J.H. performed research; and A.K., R.A., and W.A.G. wrote the paper.

Attached Files

Published - PNAS-2012-Kirkpatrick-19988-93.pdf

Supplemental Material - pnas.201218051SI.pdf

Files

PNAS-2012-Kirkpatrick-19988-93.pdf
Files (1.3 MB)
Name Size Download all
md5:9d1273a87007dab3ae92242868a9b584
827.0 kB Preview Download
md5:82d1bc90f481f3671ba9411508a47d68
507.1 kB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 20, 2023